Week of Apr. 7, 2011: Company and People Notes: ATMI Forms Distribution Pact with Finesse; AAIPharma Promotes Dean Shirazi; and More. - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Week of Apr. 7, 2011: Company and People Notes: ATMI Forms Distribution Pact with Finesse; AAIPharma Promotes Dean Shirazi; and More.

ePT--the Electronic Newsletter of Pharmaceutical Technology

Company Notes

The contract and development manufacturing organization (CDMO) AAIPharma Services has relocated its compendial raw materials testing group to a new laboratory space located within the company’s Wilmington, NC, headquarters facility. The new laboratory will tie together the compendial raw-material testing laboratory and its supporting business group under one roof. The new location aims to increase turnaround times for raw materials testing; a standard 10-day turnaround will be offered for most compendial raw materials.

ATMI, a provider of single-use components, formed a distribution pact with Finesse, a manufacturer of measurement and control systems. The deal gives ATMI the right to sell Finesse T700 control systems with the ATMI single-use Integrity PadReactor system. The combined turnkey system will provide the single-use market with a ready-to-use bioreactor platform.

BASF has outlined an integration plan following the acquisition of specialty chemical company and excipient producer Cognis. The company expects to generate synergies of EUR 275 million ($391 million) of additional EBIT (earnings before interest and taxes) and have one-time integration costs of EUR 290 million ($413 million). BASF plans to maintain 26 of the 28 Cognis production sites. The Hythe, UK, site will be sold. For the site in Tromsoe, Norway, future strategic options will be evaluated. Of Cognis’ 37 nonproduction sites, 26 will be consolidated with existing BASF sites or exited, nine will remain, and two are still under review. To achieve the growth targets, 230 additional jobs will be created worldwide, mainly in the Care Chemicals division. At the same time, BASF plans to reduce 680 positions due to overlaps in functional and administrative units as well as measures to improve efficiency. This means an overall reduction of 450 positions in the BASF Group, most of which will be realized by the end of 2012. The employees will be offered a suitable position within BASF whenever possible..

Bayer HealthCare will consolidate its East Coast business at a consolidated site in New Jersey, according to an Apr. 4, 2011, press release issued by New Jersey Governor Chris Christie’s office. Bayer, which now has facilities in Wayne and Montville in New Jersey, said several sites near the company’s current locations are under consideration. The move will keep 1000 jobs in New Jersey and add up to 500 more, according to the release. A final decision on the site is expected to be made within the next few months. First moves are expected to occur in late 2011/early 2012 and proceed through the end of 2013. About 300 of the additional 500 jobs will be relocations from other Bayer sites with the other 200 expected to be created.
 
The biopharmaeutical company Biota Scientific Management received a $231 million contract from US government to produce laninamivir. The contract is designed to provide US-based manufacturing and clinical data to support
a new drug application for laninamivir to the US Food and Drug Administration.

Daiichi Sankyo began operations of vaccine joint venture, Kitasato Daiichi Sankyo, whose principle business will be manufacturing and marketing biological products for humans and animals and research and development (R&D) of vaccines with Kitasato University, other domestic and overseas universities, and research institutes.

Dainippon Sumitomo Pharma has formed a drug-development pact with the biopharmaceutical company Intercept Pharmaceutical for the development and commercialization of Intercept’s FXR agonist obeticholic acid (OCA). DSP will advance OCA in Japan and China for the treatment of chronic liver diseases, with an initial focus on primary biliary cirrhosis and nonalcoholic steatohepatitis.

Eagan Analytical Services, a contract analytical services company, acquired contract analytical service company Chemir and affiliates CAS-MI Laboratories and Cyanta Analytical Services. Chemir and CAS-MI will continue to operate under their current names, and Cyanta will begin the process to be renamed EAG Life Sciences to reflect its planned expansion of service offerings. All three laboratories will continue operations at their respective facilities.

Fujifilm Diosynth Biotechnologies, the former Merck Biomanufacturing Network, began operations under its new name following the completion of the acquisition of the Merck Biomanufacturing Network by Fujifilm. Fujifilm Diosynth Biotechnologies will provide contract biologics development and manufacturing services.

The biopharmaceutical company Gilead Sciences and Yale University signed a R&D pact that will initially span four years with an option to renew for up to 10 years. Gilead will provide $40 million in research support and basic science infrastructure development during the initial four-year period and will provide a total of up to $100 million over 10 years should the collaboration be extended through that timeframe. Gilead will have the first option to license Yale inventions that result from the collaboration.

Johnson & Johnson recalled one additional lot of Tylenol 8-Hour Extended Release Caplets 150 count bottles distributed in the United States due to moldy smell. The uncharacteristic odor is thought to be caused by the presence of trace amounts of chemicals, 2,4,6-tribromoanisole and 2,4,6-trichloroanisole.

The contract manufacturing organization (CMO) Lonza will invest £16 million ($23 million) to further develop the flexibility and capability of its Slough, UK, biopharmaceutical manufacturing facility to respond to a broader range of customer projects and strengthen its global network of biologics development and manufacturing.

Merck KGaA formed a strategic and corporate initiative, Merck Serono Israel Bioincubator Fund, which targets Israeli biotechnology start-ups. The incubator program is designed to accelerate the development of entrepreneurial start-up companies and will offer both seed financing and the opportunity of using a dedicated part of Merck Serono’s Israeli research and development center, Interlab, for their own research. Over a seven-year time span, Merck Serono will invest a total of €10 million (about $14 million).

Merck & Co. has agreed to acquire specialty pharmaceutical company Inspire Pharmaceutical. Under the terms of the agreement, Merck, through a subsidiary, will commence a tender offer for all outstanding common stock of Inspire at a price of $5.00 per share in cash, a 26% premium to the closing price of Inspire's common stock on April 4, 2011. The transaction has a total cash value of approximately $430 million.

CMO Suven Life Sciences received FDA approval as part of the renewal inspection process for its API (active pharmaceutical ingredient) manufacturing facility in Hyderabad, India.

The specialty pharmaceutical company Valeant Pharmaceuticals made a $5.7 billion bid for the biopharmaceutical company Cephalon. Valeant plans to propose a slate of directors to replace Cephalon's board with its own nominees.

People Notes

The CDMO AAIPharma has promoted Dean Shirazi, PhD, to vice-president, analytical development.

The CMO AMRI named Peter J. Hansbury vice-president of aseptic services. In this role, he will assume leadership for AMRI's aseptic fill-finish facility located in Burlington, Massachusetts.

Daiichi Sankyo Inc., the US operations of the Japan-based Daiichi Sankyo, has hired John Gargiulo as the new president and chief executive officer.

The biopharmaceutical company Generex Biotechnology made several management changes and has appointed John Barratt, chairman of the company's board of directors. The company has also named Mark Fletcher as president and CEO. In addition, the board has appointed David Brusegard, PhD, as chief operating officer and current vice-president of finance, Stephen Fellows, as acting chief financial officer of Generex to complete its new management team. Gerald Bernstein, MD, will continue as the company's vice-president for medical affairs.

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here